Business
Man Lighting Cigar With Money
Getty Images
Word on the street

Corporate mentions of ESG and diversity have dropped sharply amid backlash

Caring about diversity and corporate governance is so 2021.

Rani Molla

These days companies are afraid to do good — or at least to talk about it.

Most recently, rural lifestyle retailer Tractor Supply cut its diversity, equity and inclusion (DEI) efforts following conservative backlash against things like Pride decorations and inclusive hiring practices.

As the Wall Street Journal reported earlier this year, ESG — companies’ previously much-touted environmental, social, and governance efforts — has become sort of a dirty word and diversity goals are disappearing from annual reports. It looks like related terms too are feeling the freeze, as executives try to escape ire — and regulation — over the “woke mind virus.” 

Terms like “diversity,” “responsibility,” “governance,” and “climate change” all seem to have peaked in the last few years on earnings calls, according to data from FactSet. Companies haven’t mentioned “Black lives matter” on an earnings call in over a year.

Firms have long faced criticism from the left over whether pronouncements about things like diversity, gender equity, and environmentalism were just PR stunts rather than meaningful action. More recently, Republican lawmakers have criticized so-called “woke capital,” fighting to steer government investment from assets that take ESG into account. 

Despite those headwinds, Bloomberg Intelligence expects global ESG assets to rise to $40 trillion by 2030, or more than a quarter of all assets under management. A survey they conducted late last year found that 85 percent of the executives and investors “reported that ESG leads to better returns, resilient portfolios and enhanced fundamental analysis.”

That said, a growing number of experts have questioned the initial research that claimed doing good was good for business, with academics unable to replicate the results of the influential 2015 McKinsey paper. In other words, companies may not just be bending to conservative pressure, but to old-fashioned pressure to deliver profits to investors.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.